Santen Pharmaceutical is one of the world’s leading specialist ophthalmic pharmaceutical companies, founded in Japan over a century ago and now serving patients all over the world. We’re the ophthalmology market leader in Japan. We’ve been active in the European market since 1994 and are enjoying strong growth in EMEA (Europe, Middle East, Africa) and worldwide. We’re passionate about improving eye health and vision for patients and making beneficial treatments accessible to patients and healthcare systems. With our sole focus being ophthalmology, we can assess, respond and act quickly in this specialist field where we have deep knowledge and experience.
With our focus on the sense of eyesight, there’s a huge and unique opportunity to improve quality of life for patients while sustaining a strong and effective commercial organisation. As populations age, patient numbers are growing, driven by conditions like glaucoma and retinal disorders. The prescription ophthalmic pharmaceutical market is growing rapidly as new treatment and diagnosis methods emerge from evolving technology. There are significant unmet patient needs in ophthalmology.
Prescription ophthalmic pharmaceuticals are our core business, accounting for over 80% of our global net sales. We also provide over the counter eye treatments and medical devices as well as nutritional products for eye health. In EMEA, we are a leader in glaucoma and dry eye treatment – areas in which our portfolio serves every stage and type of disease. We are also growing our range in eye infections, allergies, and devices for vision correction and glaucoma surgery.
With our focus on the sense of eyesight, there’s a huge and unique opportunity to improve quality of life for patients while sustaining a strong and effective commercial organisation. As populations age, patient numbers are growing, driven by conditions like glaucoma and retinal disorders. The prescription ophthalmic pharmaceutical market is growing rapidly as new treatment and diagnosis methods emerge from evolving technology. There are significant unmet patient needs in ophthalmology.
Prescription ophthalmic pharmaceuticals are our core business, accounting for over 80% of our global net sales. We also provide over the counter eye treatments and medical devices as well as nutritional products for eye health. In EMEA, we are a leader in glaucoma and dry eye treatment – areas in which our portfolio serves every stage and type of disease. We are also growing our range in eye infections, allergies, and devices for vision correction and glaucoma surgery.